Prognostic Factors of a Large Retrospective Series of Mucinous Borderline Tumors of the Ovary (Excluding Peritoneal Pseudomyxoma)
- 509 Downloads
To determine the prognosis and prognostic factors in a large series of mucinous borderline tumors of the ovary (MBOT).
Materials and Methods
A retrospective review of patients with MBOT treated or referred to our institution. Three inclusion criteria were defined: (1) centralized histological review by our expert pathologist, (2) exclusion of peritoneal pseudomyxoma and any synchronous malignant tumor in the abdominal cavity, and (3) available data on the management and outcomes of patients.
From 1997 to 2004, 97 patients fulfilled inclusion criteria (95 stage I and 2 stage II disease). Of these, 9 patients had endocervical-like subtypes, 8 patients had stromal microinvasion, and 24 had intraepithelial carcinoma. Radical and conservative surgeries were performed, respectively, in 28 and 69 patients. After a median follow-up of 48 months, 13 patients had developed 14 recurrences: 7 were borderline and 7 were invasive lesions. The probability of recurrence in the form of carcinoma 5 and 10 years after the diagnosis was, respectively, 9 and 13%. The only prognostic factor for recurrence attaining statistical significance was the use of a cystectomy (compared with other surgeries relative risk [RR] = 5.6; P = 0.003; compared with salpingo-oophorectomy RR = 5.5; P = 0.012).
In the present series of 97 MBOT, mainly early-stage disease and excluding peritoneal pseudomyxoma, the cumulative risk of recurrence in the form of invasive carcinoma at 10 years was 13%. MBOT do not appear to be such a “safe” disease. The only prognostic factor for recurrence was the use of a cystectomy, suggesting that a salpingo-oophorectomy should be preferred in cases of conservative treatment.
KeywordsOvarian Tumor Invasive Carcinoma Mucinous Tumor Pathological Review Stromal Invasion
We thank Lorna Saint Ange for editing. Acknowledgments to the following colleagues for updating the follow-up and outcomes of patients: Dr. Heurtin, Dr. Regal, Dr. Legent, Dr. Marti, Dr. Le Corre, Dr. Rouzier, Dr. Stoeckle, Dr. Floquet, Dr. Patrier Sallebert, Dr. Rossi, Dr. Quentin, Dr. Geraud, Dr. Jouatte, Dr. Baron, Dr. Collet, Dr. Auriault, Dr. Metzger, Dr. Foulques, Dr. Chabanne, Dr. Cayol, Dr. Hoock, Dr. Blanchot, Dr. Mercier, Dr. Sfairi, Dr. Fetissof, Dr. Khoudayer, Dr. Pichereau, Dr. Anger, Dr. Abbara, Dr. Henry, Dr. Cailliez, Dr. Houareau, Dr. Kessler, Dr. Aubert, Dr. Batt, Dr. Lupo, Dr. Guarnieri, Dr. Beaumont, Dr. Maes, Dr. Botti, Dr. Collin Barres, Dr. Hamdan, Dr. Le Vaguers, Dr. Barres, Dr. Deffieux, Dr. Loridon, Dr. Roy Bouzonnet, Dr. Sobole, Dr. Majer, Dr. Baillet, Dr. Tranbaloc, Dr. Jacquot, Dr. Munz Beaugrand, Dr. Truc, Dr. Jarlaud, Dr. Chevallier, Dr. Zago, Dr. Zogliani, Dr. Cohen-Aloro, Dr. Signon, Dr. Le Vagueres, Dr. De Tayrac, Dr. Pinteaux, Dr. Lelarge, Dr. Sambor, Dr. Treilleux, Dr. Marceau, and Dr. Rousseau.
- 3.Tavassoli FA, Devilee P, editors.World Health Organization: Tumours of the Breast and Female Genital Organs (WHO/IARC Classification of Tumours). IARC Press: Lyon; 2003.Google Scholar
- 4.International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987;156:263–4.Google Scholar
- 8.Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2656–64.Google Scholar
- 18.Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529–41.CrossRefPubMedGoogle Scholar
- 21.Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617–35.CrossRefPubMedGoogle Scholar
- 24.De Nictolis M, Montironi R, Tommasoni S, Valli M, Pisani E, Fabris G, et al. Benign, borderline, and well-differentiated malignant intestinal mucinous tumors of the ovary: a clinicopathologic, histochemical, immunohistochemical, and nuclear quantitative study of 57 cases. Int J Gynecol Pathol. 1994;13:10–21.CrossRefPubMedGoogle Scholar